AP2369A - Carbonylamino pyrrolopyrazoles, potent kinase inhibitors. - Google Patents

Carbonylamino pyrrolopyrazoles, potent kinase inhibitors.

Info

Publication number
AP2369A
AP2369A AP2008004506A AP2008004506A AP2369A AP 2369 A AP2369 A AP 2369A AP 2008004506 A AP2008004506 A AP 2008004506A AP 2008004506 A AP2008004506 A AP 2008004506A AP 2369 A AP2369 A AP 2369A
Authority
AP
ARIPO
Prior art keywords
pyrrolopyrazoles
carbonylamino
kinase inhibitors
potent kinase
potent
Prior art date
Application number
AP2008004506A
Other languages
English (en)
Other versions
AP2008004506A0 (en
Inventor
Liming Dong
Chuangxing Guo
Yufeng Hong
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AP2008004506A0 publication Critical patent/AP2008004506A0/xx
Application granted granted Critical
Publication of AP2369A publication Critical patent/AP2369A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AP2008004506A 2005-12-21 2006-12-12 Carbonylamino pyrrolopyrazoles, potent kinase inhibitors. AP2369A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75334905P 2005-12-21 2005-12-21
US86493206P 2006-11-08 2006-11-08
PCT/IB2006/003646 WO2007072153A2 (en) 2005-12-21 2006-12-12 Carbonylamino pyrrolopyrazoles, potent kinase inhibitors

Publications (2)

Publication Number Publication Date
AP2008004506A0 AP2008004506A0 (en) 2008-06-30
AP2369A true AP2369A (en) 2012-02-29

Family

ID=38189022

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2008004506A AP2369A (en) 2005-12-21 2006-12-12 Carbonylamino pyrrolopyrazoles, potent kinase inhibitors.

Country Status (27)

Country Link
US (1) US7884117B2 (xx)
EP (1) EP1979356B1 (xx)
JP (1) JP4635089B2 (xx)
KR (1) KR101029167B1 (xx)
AP (1) AP2369A (xx)
AU (1) AU2006327866B2 (xx)
BR (1) BRPI0620354A2 (xx)
CA (1) CA2634381C (xx)
CR (1) CR10094A (xx)
CU (1) CU23751B7 (xx)
DK (1) DK1979356T3 (xx)
EA (1) EA015513B1 (xx)
EC (1) ECSP088558A (xx)
ES (1) ES2435405T3 (xx)
GE (1) GEP20104974B (xx)
HK (1) HK1128290A1 (xx)
HR (1) HRP20130976T1 (xx)
IL (1) IL191776A (xx)
MA (1) MA30076B1 (xx)
ME (1) ME00006B (xx)
MY (1) MY151455A (xx)
NO (1) NO20082482L (xx)
NZ (1) NZ568692A (xx)
PL (1) PL1979356T3 (xx)
PT (1) PT1979356E (xx)
RS (2) RS20080281A (xx)
WO (1) WO2007072153A2 (xx)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL385265A1 (pl) * 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej
CA2744987C (en) 2008-12-02 2018-01-16 Chiralgen, Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
AU2010270714B2 (en) 2009-07-06 2015-08-13 Wave Life Sciences Ltd. Novel nucleic acid prodrugs and methods use thereof
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
EP2620428B1 (en) * 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
EP2640369A1 (en) 2010-11-17 2013-09-25 F.Hoffmann-La Roche Ag Methods of treating tumors
US8771682B2 (en) 2011-04-26 2014-07-08 Technische Universtität Dresden Methods and compositions for reducing interleukin-4 or interleukin-13 signaling
SG10201700554VA (en) 2011-07-19 2017-03-30 Wave Life Sciences Pte Ltd Methods for the synthesis of functionalized nucleic acids
JP6106685B2 (ja) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
RU2014141018A (ru) 2012-03-16 2016-05-10 Ф. Хоффманн-Ля Рош Аг Способы лечения меланомы ингибиторами рак1
BR112015000723A2 (pt) 2012-07-13 2017-06-27 Shin Nippon Biomedical Laboratories Ltd adjuvante de ácido nucléico quiral
SG11201500239VA (en) 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
WO2014012081A2 (en) 2012-07-13 2014-01-16 Ontorii, Inc. Chiral control
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
EP3057955B1 (en) 2013-10-18 2018-04-11 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
WO2015058140A1 (en) 2013-10-18 2015-04-23 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
US10149905B2 (en) 2014-01-15 2018-12-11 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
JPWO2015108046A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
MX2016009290A (es) 2014-01-16 2017-02-28 Wave Life Sciences Ltd Diseño quiral.
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
KR102575327B1 (ko) 2014-10-31 2023-09-07 유비이 가부시키가이샤 치환 디히드로피롤로피라졸 화합물
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
JP6861166B2 (ja) 2015-03-27 2021-04-21 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
JP6787314B2 (ja) * 2015-06-15 2020-11-18 宇部興産株式会社 置換ジヒドロピロロピラゾール誘導体
WO2017044858A2 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2017144546A1 (en) 2016-02-23 2017-08-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of nasopharyngeal carcinoma
WO2020100944A1 (ja) 2018-11-14 2020-05-22 宇部興産株式会社 ジヒドロピロロピラゾール誘導体
WO2020140098A1 (en) * 2018-12-28 2020-07-02 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
US20220220480A1 (en) 2019-04-17 2022-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
EP4073102A4 (en) 2019-12-12 2024-05-08 Ting Therapeutics LLC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF HEARING LOSS
WO2021198511A1 (en) 2020-04-03 2021-10-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of sars-cov-2 infection
WO2022008597A1 (en) 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012242A2 (en) * 2000-08-10 2002-02-14 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2004056827A2 (en) * 2002-12-19 2004-07-08 Pharmacia Italia Spa Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
WO2005030776A1 (en) * 2003-09-23 2005-04-07 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060135508A1 (en) 2002-07-25 2006-06-22 Manuela Villa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
GB0229526D0 (en) 2002-12-19 2003-01-22 Astrazeneca Ab Chemical compounds
US8067591B2 (en) 2005-01-10 2011-11-29 Agouron Pharmaceuticals, Inc. Pyrrolopyrazole, potent kinase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012242A2 (en) * 2000-08-10 2002-02-14 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2004056827A2 (en) * 2002-12-19 2004-07-08 Pharmacia Italia Spa Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
WO2005030776A1 (en) * 2003-09-23 2005-04-07 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors

Also Published As

Publication number Publication date
ES2435405T3 (es) 2013-12-19
HRP20130976T1 (hr) 2013-11-22
IL191776A (en) 2013-03-24
NO20082482L (no) 2008-07-02
MEP0808A (xx) 2010-02-10
WO2007072153A8 (en) 2008-08-14
JP2009520805A (ja) 2009-05-28
US7884117B2 (en) 2011-02-08
KR20080080567A (ko) 2008-09-04
CR10094A (es) 2008-08-01
EP1979356A2 (en) 2008-10-15
AP2008004506A0 (en) 2008-06-30
CU20080115A7 (es) 2010-08-30
DK1979356T3 (da) 2013-11-18
HK1128290A1 (en) 2009-10-23
EP1979356B1 (en) 2013-09-18
IL191776A0 (en) 2008-12-29
ECSP088558A (es) 2008-07-30
CU23751B7 (es) 2012-01-31
AU2006327866A1 (en) 2007-06-28
MY151455A (en) 2014-05-30
CA2634381C (en) 2011-03-08
JP4635089B2 (ja) 2011-02-16
RS53029B (en) 2014-04-30
PT1979356E (pt) 2013-11-21
RS20080281A (xx) 2009-09-08
WO2007072153A2 (en) 2007-06-28
NZ568692A (en) 2011-07-29
BRPI0620354A2 (pt) 2011-11-08
EA015513B1 (ru) 2011-08-30
GEP20104974B (en) 2010-04-26
PL1979356T3 (pl) 2014-01-31
KR101029167B1 (ko) 2011-04-12
CA2634381A1 (en) 2007-06-28
ME00006B (me) 2010-02-10
EA200801291A1 (ru) 2008-12-30
US20090318440A1 (en) 2009-12-24
WO2007072153A3 (en) 2007-10-25
MA30076B1 (fr) 2008-12-01
AU2006327866B2 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
AP2369A (en) Carbonylamino pyrrolopyrazoles, potent kinase inhibitors.
AP2007004061A0 (en) Pyrrolopyrazoles, potent kinase inhibitors
EG25264A (en) Biphenyl-n-(4-pyridyl) methylsulfonamides.
AP2402A (en) Amine derivatives.
IL190078A0 (en) Kinase inhibitors
EG25271A (en) Fungicidal combinations.
GB2424882B (en) Selective kinase inhibitors
SI2270008T1 (sl) 8-heteroaril-3-alkil-1,3-dihidro-imidazo(4,5-c)kinolin-2-oni kot inhibitorji PI-3 kinaz
IL192033A0 (en) Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
AP2281A (en) Novel compounds.
SI1943243T1 (sl) Inhibotorji kinaz
AP2006003659A0 (en) Azabenzofuran substituted thioureas, inhibitors ofviral replication
ZA200805028B (en) Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor Xla inhibitors
AP2337A (en) Motilide compounds.
AP2006003791A0 (en) 1-Heterocyclyl-1,5-dihydro-pyridoÄ3,2-BÜindol-2-ones
NL1031384A1 (nl) Gesubstitueerde aryl-1,4-pyrazinederivaten.
GB0505823D0 (en) Boardmate, boardmate adjustable
ZA200804667B (en) Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
ITRM20050033U1 (it) Semicabina per fumatori.
ITTO20050072U1 (it) Armadio-espositore, particolarmente per tabaccherie
IL189985A0 (en) Kinase inhibitors
ZA200803287B (en) Kinase inhibitors
CY2449B1 (en) Multiple srengthened carton.
PL378279A1 (pl) Układ do osuszania gazów zwłaszcza dla komór klimatycznych
ITPD20040243A1 (it) Inserto per sottotacchi.